Mantle cell lymphoma (MCL) is a challenging B-cell non-Hodgkin lymphoma with a poor prognosis and frequent relapses. While treatment advancements such as rituximab and Bruton tyrosine kinase inhibitors (BTKi) like ibrutinib have improved outcomes, novel treatments are continually sought. Zanubrutinib, a second-generation BTKi, promises reduced side effects due to its high selectivity and reduced off-target inhibition.
View Article and Find Full Text PDFWeekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making.
View Article and Find Full Text PDFBackground: Globally, midwifery-led birthing units are associated with favourable clinical outcomes and positive birth experiences. As part of our evaluation of Canada's first Alongside Midwifery Unit (AMU) at Markham Stouffville Hospital, we sought to explore and compare birth experiences and satisfaction among midwifery clients who gave birth on the AMU with midwifery clients who gave birth on the traditional obstetric unit prior to AMU implementation.
Methods: We conducted a structured, online, cross-sectional survey of midwifery clients in the six months before, and up to 18 months after, opening of the AMU at Markham Stouffville Hospital, Ontario Canada.